These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 15703422

  • 1. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.
    N Engl J Med; 2005 Feb 10; 352(6):570-85. PubMed ID: 15703422
    [Abstract] [Full Text] [Related]

  • 2. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP.
    N Engl J Med; 2005 Feb 10; 352(6):586-95. PubMed ID: 15703423
    [Abstract] [Full Text] [Related]

  • 3. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD, Wong JB, Muñoz A, Sonnenberg FA.
    Arch Intern Med; 1993 May 10; 153(9):1107-16. PubMed ID: 8481077
    [Abstract] [Full Text] [Related]

  • 4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.
    Antivir Ther; 2006 May 10; 11(1):63-72. PubMed ID: 16518961
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.
    Lung Cancer; 2005 May 10; 48(2):171-85. PubMed ID: 15829317
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department.
    Dowdy DW, Rodriguez RM, Hare CB, Kaplan B.
    Acad Emerg Med; 2011 Jul 10; 18(7):745-53. PubMed ID: 21762236
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M, Swiss HIV Cohort Study.
    PLoS One; 2007 Jan 24; 2(1):e173. PubMed ID: 17245449
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, Sanders GD, Owens DK.
    AIDS; 2006 Nov 14; 20(17):2207-15. PubMed ID: 17086061
    [Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA.
    AIDS; 2004 Dec 03; 18(18):2411-8. PubMed ID: 15622317
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.
    Antivir Ther; 2004 Feb 03; 9(1):27-36. PubMed ID: 15040534
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands.
    Rozenbaum MH, Verweel G, Folkerts DK, Dronkers F, van den Hoek JA, Hartwig NG, de Groot R, Postma MJ.
    Int J STD AIDS; 2008 Oct 03; 19(10):668-75. PubMed ID: 18824618
    [Abstract] [Full Text] [Related]

  • 12. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA, Grobman WA.
    Am J Obstet Gynecol; 2005 Apr 03; 192(4):1153-61. PubMed ID: 15846195
    [Abstract] [Full Text] [Related]

  • 13. Routine screening for HIV infection--timely and cost-effective.
    Bozzette SA.
    N Engl J Med; 2005 Feb 10; 352(6):620-1. PubMed ID: 15703428
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of HIV screening in acute care settings.
    Owens DK, Nease RF, Harris RA.
    Arch Intern Med; 1996 Feb 26; 156(4):394-404. PubMed ID: 8607724
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S, Kurotaki T, Nakasone T, Honda M, Boon-Long J, Sawanpanyalert P, Kimura K.
    Jpn J Infect Dis; 2006 Jun 26; 59(3):168-73. PubMed ID: 16785697
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO.
    AIDS Care; 2006 Feb 26; 18(2):109-20. PubMed ID: 16338768
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, Hamers FF.
    AIDS; 2006 Aug 22; 20(13):1753-61. PubMed ID: 16931940
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD, Holtgrave DR, Pinkerton HJ.
    Arch Intern Med; 1997 Sep 22; 157(17):1972-80. PubMed ID: 9308509
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM, Tsevat J.
    Med Decis Making; 2004 Sep 22; 24(1):30-9. PubMed ID: 15005952
    [Abstract] [Full Text] [Related]

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Sep 22; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.